Bayer sees IPO cash as war chest for new consumer deals

Once Bayer raises the billions it anticipates from an IPO of its plastics business, it plans to pay off debt. But after that? Expect some OTC acquisitions, the company's CEO says.

Bayer CEO Marijn Dekkers

Bayer is spinning off plastics in a move away from its chemical roots, preferring to focus on its fast-growing pharma unit and its assets in an expanding consumer health space. The proceeds will help Bayer march toward its goal of becoming the largest OTC player in the world, chief exec Marijn Dekkers told the Financial Times, tabbing the consumer health market as an "obvious consolidation play."

To see that, one just needs to look at the array of different suppliers to the shelves of pharmacy giants like Boots in the U.K., he points out. "That means that nobody has really optimized their relationship with Boots yet," he told the paper.

And Bayer wants to be at the front of the pack. It's shown as much so far this year, grabbing China's Dihon Pharmaceuticals before shelling out $14.2 billion for Merck's ($MRK) consumer unit.

"We believe that critical mass is important," he told the Times. "You need to be a large player there. If you don't participate in consolidation you fall behind, and that is competitively dangerous."

Other drugmakers have received that memo, too. Fellow pharma giants GlaxoSmithKline ($GSK) and Novartis ($NVS) this April agreed to team up on a consumer health joint venture, which will take the top spot in the OTC market after the deal closes next year. And then there's Perrigo ($PRGO), which will vault into the top 5 after inking a $4.5 billion deal for Belgium's Omega Pharma last month, the FT notes.

As Bayer looks to snap up future OTC targets, it might have a slew of additional competitors to fend off, too. Sanofi ($SNY), for one, has actively grown its consumer health business since buying out Tennessee's Chattem, and it was rumored to be a potential bidder for Omega--along with Bayer itself. Reckitt Benckiser, which entered a two-horse race for the Merck unit this year before ceding it to the German company, plans to spin off its underperforming pharma unit to double down on OTC, too.

- read the FT story

Special Reports: The top 10 pharma companies by 2013 revenue - Bayer HealthCare | Pharma's top 10 M&A deals of H1 2014 - Bayer/Merck Consumer Health

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.